Skip to main content
PMC home page
The Yale Journal of Biology and Medicine logoLink to The Yale Journal of Biology and Medicine
. 1997 Sep-Dec;70(5-6):549–554.

Indirect antiproliferative effect of the somatostatin analog octreotide on MIA PaCa-2 human pancreatic carcinoma in nude mice.

G Weckbecker 1, F Raulf 1, D Bodmer 1, C Bruns 1
PMCID: PMC2589263  PMID: 9825482

Abstract

Analogs of somatostatin (SRIF) such as octreotide exert antiproliferative effects that are mediated directly by tumoral SRIF receptors or indirectly by down-modulation of factors that stimulate tumor growth. Direct and indirect antiproliferative effects have been demonstrated in certain SRIF receptor-positive and -negative human breast cancer models in nude mice, respectively. These antiproliferative mechanisms are also being explored in other cancer types including pancreatic cancer. While clinical pilot studies have indicated that a fraction of pancreatic adenocarcinomas respond to high-dose octreotide treatment, it is known from receptor autoradiographic and scintigraphic studies that human pancreatic carcinomas fail to express SRIF receptors, in contrast to rat pancreatic carcinomas or human endocrine pancreatic cancer. Studies on the potential anticancer effect of octreotide on the growth of experimental human pancreatic cancer and its SRIF receptor status have been controversial. Therefore, we investigated in vivo the effects of octreotide on the growth of MIA PaCa-2 human pancreatic carcinomas raised from cultured cells with a low passage number after receipt from the American Type Culture Collection. Nude mice bearing MIA PaCa-2 tumors were treated with a single injection of the recently developed octreotide long-acting release formulation, "SMS pa LAR." This treatment was well tolerated and resulted in a highly significant inhibition of tumor growth during weeks three and eight after administration. MIA PaCa-2 tumors were removed after eight weeks and processed for RT-PCR analysis using probes specific for each of the five somatostatin receptor subtypes sst1-sst5. This analysis revealed that MIA PaCa-2 tumors, like human pancreatic adenocarcinomas, do not express any of the five SRIF receptor subtypes, suggesting an indirect mode of tumor growth inhibition. In summary, the depot formulation SMS pa LAR exerted long-lasting antiproliferative effects in SRIF receptor-negative human pancreatic carcinomas in nude mice.

Full text

PDF
549

Images in this article

553Figure 3
on p.553

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barrie R., Woltering E. A., Hajarizadeh H., Mueller C., Ure T., Fletcher W. S. Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent. J Surg Res. 1993 Oct;55(4):446–450. doi: 10.1006/jsre.1993.1167. [DOI] [PubMed] [Google Scholar]
  2. Buscail L., Delesque N., Estève J. P., Saint-Laurent N., Prats H., Clerc P., Robberecht P., Bell G. I., Liebow C., Schally A. V. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2315–2319. doi: 10.1073/pnas.91.6.2315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fisher W. E., Muscarella P., O'Dorisio T. M., O'Dorisio M. S., Kim J. A., Doran T. A., Sabourin C. L., Schirmer W. J. Expression of the somatostatin receptor subtype-2 gene predicts response of human pancreatic cancer to octreotide. Surgery. 1996 Aug;120(2):234–241. doi: 10.1016/s0039-6060(96)80293-5. [DOI] [PubMed] [Google Scholar]
  4. Gillespie J., Poston G. J., Schachter M., Guillou P. J. Human pancreatic cancer cell lines do not express receptors for somatostatin. Br J Cancer. 1992 Sep;66(3):483–487. doi: 10.1038/bjc.1992.300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Huynh H., Pollak M. Enhancement of tamoxifen-induced suppression of insulin-like growth factor I gene expression and serum level by a somatostatin analogue. Biochem Biophys Res Commun. 1994 Aug 30;203(1):253–259. doi: 10.1006/bbrc.1994.2175. [DOI] [PubMed] [Google Scholar]
  6. Lamberts S. W., Krenning E. P., Reubi J. C. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev. 1991 Nov;12(4):450–482. doi: 10.1210/edrv-12-4-450. [DOI] [PubMed] [Google Scholar]
  7. Radulovic S., Comaru-Schally A. M., Milovanovic S., Schally A. V. Somatostatin analogue RC-160 and LH-RH antagonist SB-75 inhibit growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice. Pancreas. 1993 Jan;8(1):88–97. doi: 10.1097/00006676-199301000-00016. [DOI] [PubMed] [Google Scholar]
  8. Raulf F., Pérez J., Hoyer D., Bruns C. Differential expression of five somatostatin receptor subtypes, SSTR1-5, in the CNS and peripheral tissue. Digestion. 1994;55 (Suppl 3):46–53. doi: 10.1159/000201201. [DOI] [PubMed] [Google Scholar]
  9. Reubi J. C., Horisberger U., Laissue J. High density of somatostatin receptors in veins surrounding human cancer tissue: role in tumor-host interaction? Int J Cancer. 1994 Mar 1;56(5):681–688. doi: 10.1002/ijc.2910560513. [DOI] [PubMed] [Google Scholar]
  10. Serri O., Brazeau P., Kachra Z., Posner B. Octreotide inhibits insulin-like growth factor-I hepatic gene expression in the hypophysectomized rat: evidence for a direct and indirect mechanism of action. Endocrinology. 1992 Apr;130(4):1816–1821. doi: 10.1210/endo.130.4.1547711. [DOI] [PubMed] [Google Scholar]
  11. Srikant C. B., Shen S. H. Octapeptide somatostatin analog SMS 201-995 induces translocation of intracellular PTP1C to membranes in MCF-7 human breast adenocarcinoma cells. Endocrinology. 1996 Aug;137(8):3461–3468. doi: 10.1210/endo.137.8.8754775. [DOI] [PubMed] [Google Scholar]
  12. Upp J. R., Jr, Olson D., Poston G. J., Alexander R. W., Townsend C. M., Jr, Thompson J. C. Inhibition of growth of two human pancreatic adenocarcinomas in vivo by somatostatin analog SMS 201-995. Am J Surg. 1988 Jan;155(1):29–35. doi: 10.1016/s0002-9610(88)80254-x. [DOI] [PubMed] [Google Scholar]
  13. Weckbecker G., Liu R., Tolcsvai L., Bruns C. Antiproliferative effects of the somatostatin analogue octreotide (SMS 201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro. Cancer Res. 1992 Sep 15;52(18):4973–4978. [PubMed] [Google Scholar]
  14. Weckbecker G., Raulf F., Stolz B., Bruns C. Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol Ther. 1993 Nov;60(2):245–264. doi: 10.1016/0163-7258(93)90009-3. [DOI] [PubMed] [Google Scholar]

Articles from The Yale Journal of Biology and Medicine are provided here courtesy of Yale Journal of Biology and Medicine

RESOURCES